Pharmacy benefit managers and health carriers required to use prescription drug rebates and other compensation to benefit covered persons, and report required.
HF1075 would require pharmacy benefit managers (PBMs) and health carriers to use prescription drug-related compensation from manufacturers to lower costs for covered persons. In general, the bill directs all compensation tied to a prescription drug benefit—such as rebates, discounts, credits, fees, grants, chargebacks, and similar payments—to be passed through to the covered person at the point of sale to reduce out-of-pocket costs for that specific prescription drug.
The bill also creates an exception when the person’s cost-sharing amount is already lower than the amount that would result after applying the compensation. In that case, the PBM or health carrier may retain the compensation, but it must use the retained amount in plan design to offset future premiums or other costs for covered persons. The bill applies this requirement to state employee group insurance program contracts as well, and it requires annual compliance reporting to the commissioner beginning March 1, 2026. The effective date is January 1, 2026.
HF1075 would add a new section to Minnesota Statutes chapter 62W governing how PBMs and health carriers handle manufacturer compensation tied to prescription drugs. It would change current plan and rebate practices by requiring point-of-sale pass-through of compensation to reduce patient cost-sharing, while also imposing a reporting obligation to show compliance. The bill would affect PBMs, health carriers, state employee health coverage contracts, and covered persons who pay copayments or coinsurance for prescription drugs.
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the available record. Based on the bill text alone, the measure appears consumer-focused and intended to lower prescription drug costs for insured patients. Its structure suggests a policy preference for transparency and direct patient benefit from drug rebates and similar compensation.
The main policy tension in the bill is how to handle compensation when passing all of it through at the point of sale would exceed the patient’s actual cost-sharing obligation. The bill allows PBMs and health carriers to retain compensation in that situation, but only if they use it to offset future premiums or other costs, which may raise questions about administrative complexity and whether savings are fully realized by consumers. Potentially affected parties include PBMs, insurers, employers, and state health plans, while supporters are likely to be consumer advocates and those seeking lower drug costs.